Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 885

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 7A
Chunk 885
---
 precision medicine.

RENC
 
Developing a predicative artificial intelligence based
diagnostic methodology for the use of earlier cancer detection 

The Company’s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

    Schedule of segment operating loss and
    asset information 

    Operating loss 
    Assets
  
    United States (RENB) 
    $15,530,056  
    $1,907,647 
  
    United States (BioSymetrics) 
     237,880  
     6,109,643 
  
    Netherlands (RENC) 
     173,198,066  
     213,550 

    $188,966,002  
    $8,230,840 

The chief
operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate
available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by
benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are
used in assessing the performance of the segment.

Information
regarding each reportable segment for the year ended June 30, 2025 is as follows:

    Schedule of information regarding segment reporting 

    RENB 
    BioSymetrics 
    RENC 
    Total
  
    General and administrative 
    $14,904,855  
    $211,401  
    $2,763,794  
    $17,880,050 
  
    Research and development 
     502,896  
     26,029  
     8,503  
     537,428 
  
    Goodwill impairment 
     —  
     —  
     170,419,429  
     170,419,429 
  
    Depreciation and amortization 
     122,305  
     450